Description
Indications
- Afatinib is a first-line treatment for people with non-small cell lung cancer.
- (NSCLC) whose tumours have exon 19 deletions or exon 21 duplications in the epidermal growth factor receptor (EGFR)
- A test that the FDA approves found 21 (L858R) substitution mutations.
- Limitation of Use: The safety and effectiveness of Afatinib in patients whose
- There are other EGFR changes in tumours.
Dosage & Administration
Afatinib should be taken by mouth once a day, at a dose of 40 mg, until the disease gets worse or there is no.
The patient could no longer handle it. Take Afatinib at least 1 hour before or 2 hours after a Meal.
A missed dose shouldn’t be taken within 12 hours of the next dose.
Side Effects
- diarrhoea
- rash/dermatitis acneiform
- stomatitis
- paronychia
- dry skin
- decreased appetite
- pruritus
Overdose
Two healthy teenagers who took 360 mg of Afatinib each were found to have overdosed. part of mixed drug ingestion) that causes nausea, vomiting, asthenia, dizziness, headache, pain in the stomach and a high amylase
Storage
Keep Afanix away from light and in a cool, dry place. Keep out of children’s reach.
Reviews
There are no reviews yet.